A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
An Open-label, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Biological Effects of VG2062 in Patients With Advanced Solid Tumors.
Shanghai Virogin Biotech Co., Ltd.
30 participants
Mar 18, 2026
INTERVENTIONAL
Conditions
Summary
VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2062, and recommended dose of VG2062 for Phase II trials.
Eligibility
Inclusion Criteria4
- Signed written informed consent form.
- Age 18 to 75 years (inclusive), male or female.
- Subject with advanced malignant solid tumors who have failed standard treatment and for whom there is no effective treatment at this stage.
- Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception during the trial and for at least 90 days after dosing; females of childbearing potential must have a negative blood pregnancy test 7 days before enrollment.
Exclusion Criteria8
- Subjects who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
- Subjects who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
- In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on.
- Other active uncontrolled infection.
- Known alcohol or drug dependence.
- Subjects with mental disorders or poor compliance.
- Women who are pregnant or breastfeeding.
- Subjects in the opinion of the investigator are not suitable for this clinical study due to other serious systemic diseases or other reasons.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1. Dose level 1 2. Dose level 2 3. Dose level 3 4. Dose level 4 5. Dose level 5
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07262164